Intermittent versus Continuous Androgen Deprivation in Prostate Cancer
Maha Hussain(University of Michigan), Ian M. Thompson, Donna L. Berry(Dana-Farber Cancer Institute), E. David Crawford(University of Colorado Hospital), Carol M. Moinpour(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Catherine M. Tangen(Fred Hutch Cancer Center), Glenn Liu(University of Wisconsin Carbone Cancer Center), David I. Quinn(University of Southern California), Bryan Donnelly, Benjamin Ely(SWOG Cancer Research Network), Derek Raghavan(University of Southern California), Nicholas J. Vogelzang(Comprehensive Cancer Centers of Nevada), George Wilding(The University of Texas MD Anderson Cancer Center), Ulka N. Vaishampayan(Wayne State University), Stephen M. Prescott(University of Utah), Peter Venner(Cancer Institute (WIA)), Paul F. Schellhammer(Eastern Virginia Medical School), S.K. Sundaram(Mid Yorkshire Hospitals NHS Trust), Celestia S. Higano(University of Washington), Nancy A. Dawson(University of Maryland, Baltimore), Eric J. Small(CancerCare Manitoba)
Cited by 568
Related Papers
Frailty in Older Adults: Evidence for a Phenotype
|The Journals of Gerontology Series A|2001|24.4k
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
|New England Journal of Medicine|2010|5.5k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k